Avalo Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Avalo Therapeutics

07/11/2022 12:56

* Avalo Therapeutics Inc  AVTX.OQ  reported quarterly
adjusted
earnings of 34 cents​​ per share for the quarter ended in
September. The mean expectation of three analysts for the
quarter was for a loss of $1.09 per share.
    * Revenue rose 1,007.3% to $14.95 million from a year ago;
analysts expected $1.08 million. 
    * Avalo Therapeutics Inc's reported EPS for the quarter was
34
cents​.
    * The mean earnings estimate of analysts had risen by
about 17.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Avalo Therapeutics Inc shares had risen by 104.2% this
quarter and lost 66.8% so far this year.
    * The company reported quarterly net income of $3.19
million.
    * Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $17.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
7 at 12:56 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -1.09          0.34           Beat
 Jun. 30 2022      -1.77          -1.38          Beat
 Mar. 31 2022      -1.60          -2.40          Missed
 Dec. 31 2021      -1.90          -1.92          Missed